INOVIO (NASDAQ:INO), a US-based biotechnology company focused on developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, said on Thursday that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.

The Compensation Committee of INOVIO's board of directors approved the award of an option to purchase 1,302 shares of common stock with a grant date of 30 September 2025 to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of USD2.34, the closing price of INOVIO's common stock on 30 September 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the grant date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates.